{
  "meta": {
    "disclaimer": "Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service.",
    "terms": "https://open.fda.gov/terms/",
    "license": "https://open.fda.gov/license/",
    "last_updated": "2026-04-01",
    "results": {
      "skip": 0,
      "limit": 1,
      "total": 1
    }
  },
  "results": [
    {
      "status": "Terminated",
      "city": "Norwalk",
      "state": "CA",
      "country": "United States",
      "classification": "Class I",
      "openfda": {},
      "product_type": "Drugs",
      "event_id": "63017",
      "recalling_firm": "Samantha Lynn, Inc",
      "address_1": "10503 Meadow Rd",
      "address_2": "N/A",
      "postal_code": "90650",
      "voluntary_mandated": "Voluntary: Firm initiated",
      "initial_firm_notification": "Press Release",
      "distribution_pattern": "Nationwide and Canada, Australia, Germany, Brazil, Austria, United Kingdom, India, Chile, Switzerland, Thailand, Japan",
      "recall_number": "D-063-2013",
      "product_description": "Reumofan Plus Tablets, 30-count bottle per Box, (remaining label information in Spanish)",
      "product_quantity": "25,888 Boxes",
      "reason_for_recall": "Marketed without an approved NDA/ANDA: Samantha Lynn Inc. is recalling Reumofan Plus Tablets because it contains undeclared drug ingredients making it an unapproved drug.",
      "recall_initiation_date": "20120827",
      "center_classification_date": "20121123",
      "termination_date": "20130318",
      "report_date": "20121205",
      "code_info": "all lots within expiry through 2016"
    }
  ]
}